IPO· Jul 27, 2026
Coverage Timeline
newest firstAll Coverage
IPOup to $150M IPO
Apnimed Launches $150M IPO For First Sleep Apnea Pill
Shionogi-backed Apnimed launched a $150 million IPO for its once-daily obstructive sleep apnea pill AD109, targeting a Thursday pricing ahead of a Friday NASDAQ debut.
Jul 27, 2026IPO· Jul 10, 2026
Apnimed Files for Nasdaq IPO on First Oral Sleep Apnea Pill
IPO
Apnimed Files for Nasdaq IPO on First Oral Sleep Apnea Pill
Apnimed, a Shionogi-backed clinical-stage biotech, filed for a Nasdaq IPO under ticker APMD as its lead drug candidate Oxnimbi -- the first investigational oral pill for obstructive sleep apnea -- awaits an FDA decision expected in Q1 2027.
Jul 10, 2026